Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.
Research Chemistry, Novo Nordisk A/S, Måløv, Denmark.
Nat Commun. 2024 Nov 30;15(1):7162. doi: 10.1038/s41467-024-51005-5.
C-terminal α-amidated peptides are attractive therapeutic targets, but preparative methods to access amidated pharmaceuticals are limited both on lab and manufacturing-scale. Here we report a straightforward and scalable approach to the C-terminal α-amidation of peptides and proteins from cysteine-extended polypeptide precursors. This amidation protocol consists of three highly efficient steps: 1) selective cysteine thiol substitution with a photolabel, 2) photoinduced decarboxylative elimination and 3) enamide cleavage by simple acidolysis or inverse electron demand Diels-Alder reaction. We provide a blueprint for applying this protocol to the semi-recombinant production of therapeutically relevant targets where gram scale C-terminal α-amidation is achieved in a photoflow reactor on a recombinantly prepared peptide YY analogue and a GLP-1/amylin co-agonist precursor peptide. Robust performance of this reaction cascade in flow highlights the potential of this chemistry to enable amidated drug leads to enter development that would not be viable on commercial scale using existing technology.
C 端α-酰胺化肽是很有吸引力的治疗靶点,但在实验室和生产规模上,获得酰胺化药物的制备方法都很有限。在这里,我们报告了一种从半胱氨酸扩展多肽前体中对肽和蛋白质进行 C 端α-酰胺化的简单且可扩展的方法。该酰胺化方案由三个高效步骤组成:1)用光标记物选择性取代半胱氨酸巯基,2)光诱导脱羧消除,3)通过简单的酸解或逆电子需求 Diels-Alder 反应裂解烯酰胺。我们提供了一个蓝图,说明如何将该方案应用于半重组生产治疗相关靶标,在光流反应器中,通过重组制备的肽 YY 类似物和 GLP-1/胰淀素共激动剂前体肽,可在克级规模上实现 C 端α-酰胺化。该反应级联在流动相中表现出良好的性能,突出了该化学方法的潜力,使酰胺化药物先导物能够进入开发阶段,而使用现有技术在商业规模上是不可行的。